BioArctic (BIOA) 16th Annual PEGS EUROPE Presentation summary

Platform overview and scientific rationale

• BrainTransporter™ platform enables active transport of biotherapeutics across the blood-brain barrier (BBB) using transferrin receptor (TfR)-mediated mechanisms.

• Structural data and TfR biology guided the engineering of the platform, with BAT007 selected for its unique epitope and optimal positioning.

• The platform allows for increased brain exposure, broader distribution, faster and stronger efficacy, and lower dosing requirements.

• No antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity upon TfR binding, ensuring safety.

Preclinical validation and safety

• In mouse and non-human primate models, BT-Abeta mAb showed no signs of anemia, reticulocyte loss, or changes in key hematological parameters.

• No test article-related effects on cytokines, complement factors, body temperature, ECG, or blood pressure were observed in primates.

• The BT-Abeta mAb demonstrated a favorable safety profile up to 24 hours post-dose.

Brain exposure and pharmacokinetics

• BT-Abeta mAb achieved up to 70-fold higher brain exposure (Cmax) at 24 hours post-dose compared to standard Abeta mAb in primates.

• Brain:plasma ratios improved up to 89-fold in key brain regions, indicating efficient BBB crossing.

• BT-Abeta mAb distributed throughout the brain parenchyma, targeting amyloid plaques, while standard mAb accumulated in the ventricles.